Kura Investors

Investor Home

Corporate Profile
We are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Our development programs target cancers with high unmet need, including head and neck, lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.
Recent Newsmore >
09/07/17
Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
08/29/17
Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference
08/10/17
Kura Oncology Announces Pricing of Public Offering of Common Stock
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Kura Oncology Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.